Readministration of abciximab in percutaneous coronary intervention.
Due to abciximab's chimeric monoclonal antibody structure, there have been concerns about the risks of anaphylaxis, attenuated efficacy, and immune-mediated thrombocytopenia when abciximab is readministered to patients. The issue of repeated treatment with abciximab is increasingly timely and important given that 30-35% of the almost 500,000 patients undergoing PCI annually in the United States receive abciximab. It is likely that this number will increase as lessons learned from recently completed trials with abciximab become integrated into day-to-day clinical practice. Accordingly, the purpose of this review is to identify the theoretic adverse effects of abciximab readministration and their potential mechanisms, analyze the available clinical data from patients re-treated with abciximab, and to offer some practical guidelines for abciximab readministration.
Fry
E T
ET
Department of Interventional Cardiology, St Vincent Hospital, Indiana Heart Institute, Indianapolis, IN, USA.
D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects* / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D019233:Retreatment; D012306:Risk; D013921:Thrombocytopenia / Q000139:chemically induced; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab